[
  {
    "ts": "2026-02-11T05:01:02+00:00",
    "headline": "Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...",
    "summary": "Edwards Lifesciences Corp (EW) reports robust Q4 2025 results with an 11.6% sales increase, while navigating challenges in EPS and strategic spending.",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-corp-ew-q4-050102695.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "a2425bac-749c-3f16-92ee-9a0d9552c0c4",
      "content": {
        "id": "a2425bac-749c-3f16-92ee-9a0d9552c0c4",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Corp (EW) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...",
        "description": "",
        "summary": "Edwards Lifesciences Corp (EW) reports robust Q4 2025 results with an 11.6% sales increase, while navigating challenges in EPS and strategic spending.",
        "pubDate": "2026-02-11T05:01:02Z",
        "displayTime": "2026-02-11T05:01:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-corp-ew-q4-050102695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-corp-ew-q4-050102695.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T03:07:18+00:00",
    "headline": "Edwards Lifesciences Q4 Earnings Call Highlights",
    "summary": "Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and rapid growth in transcatheter mitral and tricuspid therapies (TMTT). The company said fourth-qu",
    "url": "https://www.marketbeat.com/instant-alerts/edwards-lifesciences-q4-earnings-call-highlights-2026-02-10/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "5c10140c-8c75-3965-bf92-2a9c75468335",
      "content": {
        "id": "5c10140c-8c75-3965-bf92-2a9c75468335",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and rapid growth in transcatheter mitral and tricuspid therapies (TMTT). The company said fourth-qu",
        "pubDate": "2026-02-11T03:07:18Z",
        "displayTime": "2026-02-11T03:07:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/7f35491c86968056c1ecaa0b8bd4e9ee",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Edwards Lifesciences logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2rYmEG.6Xu.y6vvx0ynVoA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/7f35491c86968056c1ecaa0b8bd4e9ee.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Xs8PRxmFhPHZk3e5PF26Ng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/7f35491c86968056c1ecaa0b8bd4e9ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/edwards-lifesciences-q4-earnings-call-highlights-2026-02-10/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-q4-earnings-call-030718626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T09:39:39+00:00",
    "headline": "February 2026's Undervalued Small Caps With Insider Action In Global Markets",
    "summary": "In February 2026, global markets are experiencing a dynamic shift as small-cap and value-oriented stocks make gains amid a cooling U.S. labor market and volatility in large-cap technology shares. With the S&P MidCap 400 and Russell 2000 indices showing solid performance, investors are increasingly interested in small-cap opportunities that demonstrate resilience and potential for growth. In this context, identifying a good stock often involves looking at companies with strong fundamentals...",
    "url": "https://finance.yahoo.com/news/february-2026s-undervalued-small-caps-093939767.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c62c1460-2b41-3d38-bbcc-8feadc782856",
      "content": {
        "id": "c62c1460-2b41-3d38-bbcc-8feadc782856",
        "contentType": "STORY",
        "title": "February 2026's Undervalued Small Caps With Insider Action In Global Markets",
        "description": "",
        "summary": "In February 2026, global markets are experiencing a dynamic shift as small-cap and value-oriented stocks make gains amid a cooling U.S. labor market and volatility in large-cap technology shares. With the S&P MidCap 400 and Russell 2000 indices showing solid performance, investors are increasingly interested in small-cap opportunities that demonstrate resilience and potential for growth. In this context, identifying a good stock often involves looking at companies with strong fundamentals...",
        "pubDate": "2026-02-11T09:39:39Z",
        "displayTime": "2026-02-11T09:39:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/3c34d9fff82f69d6a0e9da466926e19d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BGB2arDPj4P3RNJUclP8Pw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/3c34d9fff82f69d6a0e9da466926e19d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4vFPAUsjyrC8IhHGlKQ9iQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/3c34d9fff82f69d6a0e9da466926e19d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/february-2026s-undervalued-small-caps-093939767.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/february-2026s-undervalued-small-caps-093939767.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ASGTF"
            },
            {
              "symbol": "EW"
            },
            {
              "symbol": "NYAB.ST"
            },
            {
              "symbol": "^SP400"
            },
            {
              "symbol": "CLVSF"
            },
            {
              "symbol": "TOKMAN.HE"
            },
            {
              "symbol": "0450.HK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T11:10:01+00:00",
    "headline": "Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback",
    "summary": "Behind the small move in Edwards Lifesciences’ fair value estimate from about US$97.02 to about US$97.11 is a set of fine tuned assumptions that reflect the latest 2026 outlook and the fallout from the canceled JenaValve deal. Analysts are essentially sharpening their pencils on discount rates and revenue growth rather than rewriting the story. This suggests the market is focused on execution details, not a new thesis. Stay tuned to see how you can track these incremental model shifts and...",
    "url": "https://finance.yahoo.com/news/why-narrative-around-edwards-lifesciences-111001009.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "75e3947d-020c-3a70-b952-064499d8419a",
      "content": {
        "id": "75e3947d-020c-3a70-b952-064499d8419a",
        "contentType": "STORY",
        "title": "Why The Narrative Around Edwards Lifesciences EW Is Shifting After 2026 Outlook And JenaValve Setback",
        "description": "",
        "summary": "Behind the small move in Edwards Lifesciences’ fair value estimate from about US$97.02 to about US$97.11 is a set of fine tuned assumptions that reflect the latest 2026 outlook and the fallout from the canceled JenaValve deal. Analysts are essentially sharpening their pencils on discount rates and revenue growth rather than rewriting the story. This suggests the market is focused on execution details, not a new thesis. Stay tuned to see how you can track these incremental model shifts and...",
        "pubDate": "2026-02-11T11:10:01Z",
        "displayTime": "2026-02-11T11:10:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u7koo0rZkPGzBeI1l4rsQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5J1KBMD97NZX1sIZ71qfPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0ce3c3847d701ab519c25ddde4a069d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-edwards-lifesciences-111001009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-edwards-lifesciences-111001009.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-11T12:44:18+00:00",
    "headline": "Edwards reports strong 2025 despite Q4 EPS miss",
    "summary": "Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.",
    "url": "https://www.medicaldevice-network.com/news/edwards-reports-strong-2025-despite-q4-eps-miss/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "b691f19f-c7f4-3950-b1e4-135f7758816b",
      "content": {
        "id": "b691f19f-c7f4-3950-b1e4-135f7758816b",
        "contentType": "STORY",
        "title": "Edwards reports strong 2025 despite Q4 EPS miss",
        "description": "",
        "summary": "Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.",
        "pubDate": "2026-02-11T12:44:18Z",
        "displayTime": "2026-02-11T12:44:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/72adde2f900715abae6b828270714380",
          "originalWidth": 1440,
          "originalHeight": 961,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B3cy7I0Sx1a1EQviDaYnYg--~B/aD05NjE7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/72adde2f900715abae6b828270714380.cf.webp",
              "width": 1440,
              "height": 961,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ekn_vPZgqOmUXBAwNZjwUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/72adde2f900715abae6b828270714380.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/edwards-reports-strong-2025-despite-q4-eps-miss/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-reports-strong-2025-despite-124418404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]